Background: Currently, 2 coprimary end points are used by health authorities to determine the effectiveness of therapeutic interventions in patients with Crohn’s disease (CD): symptomatic remission (patient-reported outcome assessment) and endoscopic remission (ileocolonoscopy). However, there is lack of accepted biomarkers to facilitate regulatory decision-making in the development of novel therapeutics for the treatment of CD.


Biomarker, Biomarker Qualification, C-Reactive Protein, Crohn's Disease, IBD, Inflammatory Bowel Disease, Leukocyte L1 Antigen Complex, Ulcerative Colitis

Read More